LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L).
Tamas Hickish
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim
Other Remuneration - Boehringer Ingelheim
Ling-Ming Tseng
No relevant relationships to disclose
Ajay O. Mehta
No relevant relationships to disclose
Janice Tsang
No relevant relationships to disclose
Nadezhda Kovalenko
No relevant relationships to disclose
Dmitry Udovitsa
No relevant relationships to disclose
Katy Pelling
Employment or Leadership Position - Boehringer Ingelheim
Martina Maria Uttenreuther-Fischer
Employment or Leadership Position - Boehringer Ingelheim
Chiun-Sheng Huang
No relevant relationships to disclose